阿里健康是阿里巴巴集团整合线上线下（300959）医药和健康行业资源，提供一站式医疗解决方案的旗 舰平台。其主营业务包括医药自营业务、医药电商平台业务、医疗健康及数字化服务业务。凭借互联网 科技与数字技术领域的优势，以及深耕多年的品牌优势与资源，阿里健康在医生、药企商家及患者用户 间构筑起解决供需关系的关键桥梁，打造出线上线下一体化的医药健康品服务平台。 8月13日，阿里健康公布，与信达生物在杭州签署战略合作协议。双方将在诊后疾病管理、供应链、数 字化营销等多个领域展开深度合作，为消费者提供普惠可及的医药和健康管理服务。 作为中国领先的生物制药公司，信达生物已有16款创新药品上市，覆盖肿瘤、自身免疫疾病、代谢疾 病、眼病等领域。今年6月，其新一代减重药物玛仕度肽注射液获得中国国家药品监督管理局批准上 市，用于成人肥胖或超重患者的长期体重控制。 阿里健康表示，今年以来，双方在科学减重领域深度合作，信达生物的玛仕度肽注射液获批上市后，即 在阿里健康平台上线预约服务。 根据协议，双方将在诊后疾病管理、供应链、数字化营销等领域深化合作。在诊后疾病管理方面，将联 合研发基于家庭场景的诊后疾病管理系统，包括用药指导、生活 ...

Core Viewpoint - Alibaba Health and Innovent Biologics signed a strategic cooperation agreement to collaborate in post-disease management, supply chain, and digital marketing [1] Group 1: Strategic Cooperation - The partnership will focus on deep collaboration in multiple areas including post-disease management and digital marketing [1] - Both companies aim to enhance their capabilities in supply chain management, particularly for temperature-sensitive medications [1] Group 2: Supply Chain Solutions - Alibaba Health will provide customized supply chain solutions for GLP-1 class drugs that require cold chain distribution at 2-8°C [1]

8月13日，阿里健康(00241)盘中上涨3.05%，截至10:34，报5.06元/股，成交3.05亿元。 阿里健康信息技术有限公司是阿里巴巴集团的医疗健康旗舰平台，主营业务包括医药自营业务、医药电 商平台业务、医疗健康及数字化服务业务。公司依托领先的数字技术和运营能力，为亿万家庭提供普惠 便捷、高效安全的医疗健康服务，打造出线上线下一体化的医药健康品服务平台。 截至2024年年报，阿里健康营业总收入305.98亿元、净利润14.32亿元。 本文源自：金融界 作者：行情君 ...

Group 1: Macro Strategy and Market Overview - The three major equity indices continued to rise in early August, with the Shanghai Composite Index and Shenzhen Component Index both increasing by over 2%, and the ChiNext Index rising by 4.88% [20][21] - The central bank's net cash injection was 163.5 billion yuan, maintaining stable liquidity in early August, with the 7-day reverse repo rate (DR007) hovering around 1.45% [21][22] - Commodity prices showed mixed trends, with non-ferrous metals rebounding, crude oil slightly declining, and precious metals rebounding again [21] Group 2: Fixed Income and Bond Market - The upcoming issuance of 20-year special government bonds is expected to peak, presenting trading opportunities during the issuance process [2] - The new and old bond yield spread for 20-year bonds typically narrows by 0.4-1.5 basis points, with notable exceptions during significant market events [2] Group 3: Export Growth and Trade Analysis - China's exports showed steady growth in the first seven months of 2025, with a cumulative year-on-year increase of 6.1%, surpassing the 5.8% growth rate for the entire year of 2024 [23][24] - The global trade volume is expected to cool down in the second half of the year, influenced by preemptive demand in the U.S. and a decline in imports [23][24] - China's share of global exports has been increasing, with a notable rise in exports to non-U.S. regions compensating for declines in U.S. exports [24][25] Group 4: Company-Specific Insights - Yuan Da Pharmaceutical achieved a revenue of 10.784 billion yuan in 2024, a year-on-year increase of 10.59%, and a net profit of 2.286 billion yuan, up 31.28% [28][31] - The company is pioneering a new treatment for sepsis, STC3141, which has shown promising results in clinical trials [29][30] - Yuan Da's nuclear medicine segment is expanding, with significant sales growth expected from its core product, yttrium-90 microspheres, which has treated nearly 2,000 patients [30][31] Group 5: Industry Trends and Recommendations - The semiconductor industry is projected to continue its optimistic growth trajectory in 2025, driven by AI and high-performance computing [7] - The demand for storage solutions, particularly HBM and DDR5, is expected to remain strong, with price increases anticipated in the third quarter [7] - The construction materials sector, particularly cement and explosives, is expected to benefit from major infrastructure projects like the New Tibet Railway [34]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected industry index increase of over 5% in the next six months [58]. Core Insights - The report highlights the significant advancements in AI applications, particularly with the release of OpenAI's GPT-5, which is expected to accelerate commercialization in various high-frequency, high-value verticals [7][5]. - Companies like Duolingo, Palantir, and AppLovin have reported earnings that exceeded market expectations, showcasing the growing revenue contributions from AI capabilities [7][5]. - The report suggests a focus on companies with high retention rates and growth potential in sectors such as education, e-commerce, advertising, and enterprise data analysis [7][5]. Summary by Sections Key Company Financials - **Palantir**: Q2 revenue reached $1.004 billion, a 48% year-over-year increase, with a GAAP operating income of $269 million and an adjusted gross margin of 82% [14]. - **AMD**: Q2 revenue was $7.685 billion, a 32% year-over-year increase, with a gross margin of 54% and operating income of $897 million [19]. - **AppLovin**: Q2 advertising revenue grew 77% year-over-year to approximately $1.26 billion, with an adjusted EBITDA of $1.02 billion [24]. - **Duolingo**: Q2 revenue reached $252.3 million, a 41% year-over-year increase, with a gross margin of 72.4% [29]. - **Datadog**: Q2 revenue was $827 million, a 28% year-over-year increase, with a gross margin of 80.9% [33]. Global AI Developments - OpenAI launched two new large language models, gpt-oss-120b and gpt-oss-20b, which are open-weight models aimed at enhancing AI application performance [36]. - Google DeepMind introduced Genie 3, a model capable of generating interactive virtual worlds in real-time, marking a significant milestone in world modeling [40]. - Anthropic released Claude Opus 4.1, which shows improvements in coding and reasoning capabilities compared to its predecessor [45]. - OpenAI's GPT-5 was officially released, featuring a significant reduction in hallucination rates and enhanced reasoning capabilities [49].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 董事會欣然公佈，於2025年8月8日舉行之股東週年大會上，通告所載之全部決議 案已經股東以投票表決方式正式通過。 茲提述(i)阿里健康信息技術有限公司（「本公司」，連同其附屬公司統稱「本集團」）日 期為2025年7月10日之股東週年大會（「股東週年大會」）通告（「通告」）；及(ii)本公司 日期為2025年7月10日之通函（「通函」）。除文義另有所指外，本公告所用專有詞彙 與通函所界定者具有相同涵義。 股東週年大會結果 本公司董事（「董事」）會（「董事會」）欣然公佈，於2025年8月8日（星期五）上午十時三 十分假座香港銅鑼灣禮頓道8號香港銅鑼灣皇冠假日酒店28樓貴賓廳舉行之股東週 – 1 – （股份代號：00241） 於2025年8月8日舉行之 股東週年 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 阿里健康信息技術有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00241 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 1 ...

Group 1 - The core viewpoint of the article highlights the performance of Alibaba Health, which saw a stock price increase of 2.04% to 5.01 CNY per share, with a trading volume of 363 million CNY as of August 5 [1] - Alibaba Health is the flagship healthcare platform of Alibaba Group, focusing on self-operated pharmaceutical business, e-commerce platform business, and digital healthcare services [1] - The company leverages advanced digital technology and operational capabilities to provide accessible, efficient, and safe healthcare services to millions of families, creating an integrated online and offline pharmaceutical health service platform [1] Group 2 - As of the 2024 annual report, Alibaba Health reported total revenue of 30.598 billion CNY and a net profit of 1.432 billion CNY [2]

Market Performance - The CSI Cloud Computing and Big Data Theme Index increased by 1.2% [1] - The CSI Artificial Intelligence Theme Index rose by 0.5% [1] - The National Robot Industry Index decreased by 0.3% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.2% [1] - The CSI New Energy Index dropped by 3.1% [1] Company Developments - Alibaba Health launched an AI medical assistant named "Hydrogen Atom," which integrates millions of core medical journal articles and supports authoritative guideline access, semantic search, AI summarization, full-text translation, and intelligent Q&A [1] - The AI assistant is designed to help clinical medical workers and researchers quickly find necessary information, enhancing medical learning and research efficiency [1] Index Overview - The Artificial Intelligence ETF tracks the CSI Artificial Intelligence Theme Index, which comprehensively covers the AI industry chain, including upstream infrastructure, midstream models, and downstream applications [2] - The Robot ETF tracks the National Robot Industry Index, which covers the entire robot industry chain, with humanoid robots making up 53% of the index [2] - The Cloud Computing ETF tracks the CSI Cloud Computing and Big Data Theme Index, focusing on the cloud computing industry and related services [3] - The Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research, development, and production [3] - The New Energy ETF tracks the CSI New Energy Index, covering the new energy industry chain, including lithium batteries, photovoltaics, wind power, hydropower, and nuclear power [3]

7月31日，阿里健康(00241)盘中下跌2.02%，截至13:17，报4.86元/股，成交3.04亿元。 本文源自：金融界 作者：行情君 阿里健康信息技术有限公司是阿里巴巴集团的医疗健康旗舰平台，主营业务包括医药自营业务、医药电 商平台业务、医疗健康及数字化服务业务。公司依托领先的数字技术和运营能力，为亿万家庭提供普惠 便捷、高效安全的医疗健康服务，打造出线上线下一体化的医药健康品服务平台。 截至2024年年报，阿里健康营业总收入305.98亿元、净利润14.32亿元。 ...